ADVENZYMES302.20

Advanced Enzyme Tech Ltd.

· Pharma & Health
₹ CrorePeersAARTIPHARMAARTIDRUGSAGARWALEYEAKUMSALIVUSAPLLTDCORONAHCGMcap ₹3,382 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth+2.1+17.1
EBITDA Growth-4.9+17.8
EBIT Growth-6.7+19.7
Net Income Growth-2.2+29.6
EPS Growth-1.7+28.7
Total Assets Growth+5.6+13.4
Total Equity Growth+7.1+14.6
Cash from Operations Growth+0.8+10.0
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.